Connect with us

News

Clinical Trials Of Sputnik V Coronavirus Vaccine To Begin This Month In Countries Including India

Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) told that clinical trials of Sputnik V vaccine for coronavirus will begin in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil

Highlights
  • Sputnik V, a human adenoviral vector vaccine, fights COVID-19: Researchers
  • Phase I-II clinical trials of Sputnik V showed no serious adverse events
  • Sputnik V has higher level of virus-neutralizing antibodies: RDIF

Moscow: The clinical trials of Sputnik V vaccine for coronavirus will be held this month in several countries including India, confirmed Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF) on Monday (September 7). Kirill Dmitriev told Sputnik that the clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month.

“The post-registration studies involving more than 40,000 people started in Russia on August 26, before AstraZeneca has started its Phase 3 trial in the US with 30,000 participants. Clinical trials in Saudi Arabia, United Arab Emirates (UAE), the Philippines, India and Brazil will begin this month. The preliminary results of the Phase 3 trial will be published in October-November 2020,” said Kirill Dmitriev.

Also Read: Widespread COVID-19 Vaccinations Not Expected Until Mid-2021: World Health Organization

Russia was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.

On August 11, the Sputnik V vaccine developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19.

According to Russian researchers, Sputnik V is a human adenoviral vector vaccine which fights against coronavirus disease.

India has historically been a very important partner of Russia. India is one of the leading countries in production. Around 60 percent of all the vaccines in the world are produced in India. We are in close dialogue with the corresponding ministries and the India government and the leading manufacturer of the country regarding localisation of production of Sputnik V vaccine in India. And we have achieved certain agreements with the leading companies, Kirill Dmitriev said earlier in response to an ANI query on the talks between India and the Russian government on Sputnik V vaccine.

Also Read: Minimal SARS-CoV-2 Diversity Suggests Global Vaccine Is Feasible: Study

“We do recognise India and its potential to become one of the support for the production of the vaccine not only in Indian markets but for other countries too. We very much appreciate the well- balanced approach expressed by the Indian partners as from the very beginning they started asking questions how our vaccine works and we appreciate it that they did not try to attack our vaccine but try to understand it,” Kirill Dmitriev adding that their (India’s) desire to understand our vaccine got to realize that their approach based on the human adenoviral vaccine platform is the most reasonable approach.

On September 4, a medical journal The Lancet has published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy.

Also Read: Russian COVID-19 Vaccine Safe, Induces Antibody Response In Small Trials: Lancet Study

Phase I-II clinical trials of Sputnik V showed no serious adverse events (SAE, Grade 3) for any of the criteria, while the incidence of serious adverse events for other candidate vaccines ranged from 1 per cent to 25 per cent, RDIF press note stated.

“In 100 per cent of participants in the clinical trials, Sputnik V generated a stable humoral and cellular immune response. The level of virus-neutralizing antibodies of volunteers vaccinated with Sputnik V was 1.4-1.5 times higher than the level of antibodies of patients who had recovered from COVID-19,” RDIF press note further read.

Also Read: United States Of America Backs Out From Global Effort To Develop, Distribute COVID-19 Vaccine

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) 

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene.  

 

Click to comment

Leave a Reply

Your email address will not be published.

Folk Music For A Swasth India

RajasthanDay” src=

Reckitt’s Commitment To A Better Future

Expert Blog

हिंदी में पड़े

Latest Posts